Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER

(PFE)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
05/15/2019 05/16/2019 05/17/2019 05/20/2019 05/21/2019 Date
41.15(c) 41.64(c) 41.47(c) 41.59(c) 41.67(c) Last
31 803 418 24 201 579 27 692 390 23 009 069 27 267 658 Volume
+1.21% +1.19% -0.41% +0.29% +0.19% Change
More quotes
Financials (USD)
Sales 2019 53 201 M
EBIT 2019 19 478 M
Net income 2019 13 317 M
Debt 2019 32 207 M
Yield 2019 3,44%
Sales 2020 53 948 M
EBIT 2020 20 041 M
Net income 2020 14 125 M
Debt 2020 30 349 M
Yield 2020 3,61%
P/E ratio 2019 17,29
P/E ratio 2020 15,79
EV / Sales2019 4,95x
EV / Sales2020 4,85x
Capitalization 231 B
More Financials
Company
Pfizer the world's leading pharmaceutical group. Net sales break down by family of products as follows: - vaccines, oncology products and consumer medicines (59.8%); - generic medicines (40.2%): for treating cardio-vascular diseases, nervous system disorders, infectious and respiratory diseases,... 
Sector
Pharmaceuticals
Calendar
06/04 | 12:45pmPresentation
More about the company
Surperformance© ratings of Pfizer
Trading Rating : Investor Rating :
More Ratings
Latest news on PFIZER
05/20PFIZER : Confirms Initiation of EU Review of Tofacitnib with Interim Recommendat..
PU
05/18PFIZER : Eczema Candidate Meets All Goals In Phase III Study
AQ
05/17PFIZER : confirms initiation of EU review of Tofacitinib with interim recommenda..
PU
05/17PFIZER : new JAK inhibitor could come after your eczema market
AQ
05/17Pfizer, Merck KGaA clinch needed approval for Bavencio, directly competing ag..
AQ
05/16PFIZER : FDA Approves Pfizer's Fragmin for Use as a Pediatric Anticoagulant
DJ
05/16PFIZER : Merck and Pfizer Inc. - FDA Approves BAVENCIO plus Axitinib Combination..
AQ
05/16PFIZER : opens $200m clinical manufacturing plant in MA
AQ
05/16PFIZER : selects first GPCR candidate from Sosei Heptares tie-up
AQ
05/15PFIZER : Oncology to Showcase New Data from Innovative Science That Address Pati..
BU
More news
Analyst Recommendations on PFIZER
More recommendations
Sector news : Pharmaceuticals - NEC
01:42pUPDATE : N.Y. Jury Delivers $25 Million Judgment Against Johnson & Johnson -- Bl..
DJ
01:38pJOHNSON & JOHNSON : Correction to Johnson & Johnson Jury Story
DJ
01:27pJOHNSON & JOHNSON : N.Y. Jury Delivers $25 Million Judgment Against Johnson & Jo..
DJ
11:10aBAYER : hires law firm to probe Monsanto data collection
RE
10:47aMERCK AND : buys Peloton to expand its kidney cancer treatment portfolio
RE
More sector news : Pharmaceuticals - NEC
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 45,1 $
Spread / Average Target 8,4%
EPS Revisions
Managers
NameTitle
Albert Bourla Director, Chief Executive & Operating Officer
Ian C. Read Executive Chairman
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-4.54%231 237
JOHNSON & JOHNSON7.41%367 513
ROCHE HOLDING LTD.9.26%226 839
NOVARTIS11.63%207 417
MERCK AND COMPANY3.23%203 088
ABBVIE-13.42%118 000